Oxford BioDynamics subsidiary inks Asia licence

Oxford BioDynamics subsidiary Oxford BioDynamics Pte Ltd has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Ltd (NSDA).

This was to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.

Specifically for Malaysia, Oxford BioDynamics had granted its consent for NSDA to grant an exclusive sub-licence to Genting Laboratory Services Sdn Bhd, a wholly owned subsidiary of Genting Berhad, to provide the proprietary breast cancer test.

NSDA was a wholly owned subsidiary of Nova Satra Dx Pte Ltd, a Singaporean company that developed and commercialised blood-based diagnostic tests to provide the early detection of cancer. Nova Satra Dx was an associate company of Genting Berhad, a Malaysian conglomerate.